Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment

Review

Expert Opinion on Drug Metabolism & Toxicology, 15:2,113-120, DOI: 10.1080/17425255.2019.1568409
 

Introduction: Asthma is a chronic inflammatory airway disease. It occurs in a ‘severe’ form in about 8–10% of asthmatic patients. In the last decade, the development of biological drugs (e.g. monoclonal antibodies) allowed to efficiently approach severe asthma. The current therapeutic targets available are mainly those related to TH2 inflammation.

Areas covered: The main pharmacokinetic and pharmacodynamic characteristics of the monoclonal antibodies against IL-5, IL-5Ra, IL4-IL13, and IgE, that are currently marketed or understood for severe asthma are discussed in this paper.

Expert opinion: The currently available biological drugs represent an excellent therapeutic add-on to traditional drugs, especially in replacing systemic corticosteroid therapies. The different pharmacokinetic and pharmacodynamic characteristics of the drugs, despite sometime sharing the same target, would allow a better personalization of the therapy, tailoring the treatment to the characteristics of the patient.

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Which factors should be considered before escalating treatments in children with severe therapy-resistant #asthma? https://t.…
9hreplyretweetfavorite
Interasma RT @Aller_MD: Analgesics in pregnancy do not seem to cause offspring #asthma https://t.co/pcwbWUNheb
9hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/G1CYpYKwAy
9hreplyretweetfavorite
Interasma RT @Aller_MD: Mother's diet during pregnancy can impact lung-specific genes of her offspring https://t.co/cOD1iWDLx5
9hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma